We serve Chemical Name:tert-Butyl 3-bromo-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate CAS:949922-61-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![tert-Butyl 3-bromo-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate](https://a.dearchem.com/CAS2/949922-61-6.png)
Chemical Name:tert-Butyl 3-bromo-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate
CAS.NO:949922-61-6
Synonyms:tert-butyl 3-bromo-6,8-dihydro-5H-imidazo[1,2-a]pyrazine-7-carboxylate;Imidazo[1,2-a]pyrazine-7(8H)-carboxylic acid, 3-bromo-5,6-dihydro-, 1,1-dimethylethyl ester;tert-Butyl-3-brom-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-carboxylat;2-Methyl-2-propanyl 3-bromo-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate;tert-Butyl 3-bromo-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate
Molecular Formula:C11H16BrN3O2
Molecular Weight:302.168
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:432.4±35.0 °C at 760 mmHg
Density:1.5±0.1 g/cm3
Index of Refraction:1.612
PSA:47.36000
Exact Mass:301.042572
LogP:0.68
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like tert-butyl 3-bromo-6,8-dihydro-5H-imidazo[1,2-a]pyrazine-7-carboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,tert-Butyl 3-bromo-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,tert-Butyl-3-brom-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-carboxylat Use and application,tert-Butyl 3-bromo-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate technical grade,usp/ep/jp grade.
Related News: Now that Alexion’s Soliris is in AstraZeneca’s hands, the drugmaker is counting on the C5 inhibitor to help push it toward billions in sales in just a few years. But a prominent drug pricing watchdog is raising a red flag over its costs for patients with a rare neuromuscular disorder. 1-Propanethiol, 3-trimethylsilyl- manufacturers As for the consumer health unit, GSK plans to demerge it by mid-2022, during which GSK will shed at least 80% of its 68% holding in the JV to shareholders. 1-(3-fluorophenyl)pyrrole-2-carbaldehyde suppliers In the trial, 362 eligible patients were randomised (1:1) and received a fixed-dose intravenous infusion of 300mg anifrolumab or placebo every four weeks. 1,2-dibromododecane vendor & factory.
